On January 2, 2019 CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, reported that Sujal Shah, President and Chief Executive Officer, will provide a corporate overview at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 9, 2019 at 4:30pm PT (Press release, CymaBay Therapeutics, JAN 2, 2019, View Source [SID1234532334]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation can be accessed through the Investors section of the CymaBay Therapeutics corporate website at View Source The webcast will be archived on the corporate website for 90 days.

On January 2, 2018 Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, reported that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at the upcoming Biotech Showcase 2019 Conference on Monday, January 7, 2019 at 11:00 a.m. PST in San Francisco, CA (Press release, Aptose Biosciences, JAN 2, 2019, View Source [SID1234532356]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Presentation Details:

Date: Monday, January 7, 2019
Time: 11:00 a.m. PST
Location: Track Yosemite – C (Ballroom Level)
Hilton San Francisco Union Square, 333 O’Farrell Street, San Francisco, CA 94102
Webcast: View Source;tp_key=d5803514a3

The audio webcast will be archived shortly after the live event and will be available through the Aptose website at View Source

The Company will also be hosting institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place in San Francisco, on January 8 and 9, 2019.

To schedule a meeting with Aptose, investors can register on the online system managed by the Company’s US investor relations firm LifeSci Advisors, LLC, or make a request via e-mail at [email protected].

On January 2, 2019 Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") reported that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference as follows (Press release, Eagle Pharmaceuticals, JAN 2, 2019, View Source [SID1234532373]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Wednesday, January 9, 2019
Time: 2:30 p.m. Pacific Standard Time
Location: Westin St. Francis Hotel, San Francisco
Webcast:

View Source

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.eagleus.com, under the Investors Section.

On January 2, 2019 Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology and immunology, reported that management will attend the following conferences (Press release, Aclaris Therapeutics, JAN 2, 2019, View Source [SID1234532335]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Management will host investor meetings during the 2019 JP Morgan Healthcare Conference in San Francisco, CA from Monday, January 7, 2019 through Wednesday, January 9, 2019.

Dr. Neal Walker, President and Chief Executive Officer, will present at the 8th Annual Leerink Partners Global Healthcare Conference in New York, NY on Wednesday, February 27, 2019 at 10:30 AM EST. Management will also host investor meetings on Wednesday, February 27, 2019.
A live webcast of the 8th Annual Leerink Partners Global Healthcare Conference presentation may be accessed through the Company’s web site, www.aclaristx.com, on the ‘Events and Presentations’ section. An archived version of the presentation will be available for 30 days.

On January 2, 2018 Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, reported that the company is scheduled to present and subsequently participate in a Q&A session at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019 at 9:30 a.m. PT (12:30 p.m. ET) (Press release, Magenta Therapeutics, JAN 2, 2019, View Source [SID1234532357]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation and Q&A session can be accessed under the "Events & Presentations" page within the Investors & Media section of the Magenta Therapeutics website at View Source A replay of the webcast will be available on the Magenta Therapeutics website for 90 days following the event.